Thera4Care Project

About EXINI Diagnostics

EXINI Diagnostics is a pioneer in AI-powered medical image analysis, with a 25-year history originating from Lund University research. Its core technology provides quantitative, reproducible assessments of bone, cardiac, brain, and PSMA PET scans, with its flagship automated Bone Scan Index (aBSI) platform deployed at approximately 1,000 hospitals worldwide. Acquired by Progenics Pharmaceuticals in 2015 and subsequently by Lantheus Holdings in 2020, EXINI now operates as a key AI and software arm within a larger, integrated diagnostics and therapeutics company. Its products are commercial-stage, revenue-generating tools used to support precision oncology and other diagnostic workflows.

Therapeutic Areas